Avanafil: a new phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction

By Hatzimouratidis Konstantinos  

Aging Health, Vol. 6, Iss. 5, 2010-10 ,pp. : 599-605

Future Medicine

Access to resources Recommend Favorite

Salvage strategies for nonresponders to phosphodiesterase-5 inhibitor treatment for erectile dysfunction in the aging male

By Brant William O   Brock Gerald B   Lue Tom F   Gerridzen Ronald G   Bella Anthony J  

Aging Health, Vol. 3, Iss. 4, 2007-08 ,pp. : 527-542

Future Medicine

Access to resources Recommend Favorite

Salvage therapy trial for erectile dysfunction using phosphodiesterase type 5 inhibitors and vitamin E: Preliminary report

By Kondoh Nobuyuki   Higuchi Yoshihide   Maruyama Takuo   Nojima Michio   Yamamoto Shingo   Shima Hiroki  

The Aging Male, Vol. 11, Iss. 4, 2008-07 ,pp. : 167-170

Informa Healthcare

Access to resources Recommend Favorite

Office versus Home-Based Family Therapy for Runaway,Alcohol,Adolescents: Examination of Factors Associated with Treatment Attendance

By Slesnick Natasha   Prestopnik Jullian L  

Alcoholism Treatment Quarterly, Vol. 22, Iss. 2, 2004-06 ,pp. : 3-19

Haworth Press

Access to resources Recommend Favorite

Low total testosterone is associated with increased risk of incident type 2 diabetes mellitus in men: results from the Study of Health in Pomerania (SHIP)

By Schipf Sabine   Haring Robin   Friedrich Nele   Nauck Matthias   Lau Katharina   Alte Dietrich   Stang Andreas   Vöölzke Henry   Wallaschofski Henri  

The Aging Male, Vol. 14, Iss. 3, 2011-09 ,pp. : 168-175

Informa Healthcare

Access to resources Recommend Favorite